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We have investigated the role of two polymorphic sites (R190Wand N192K) on the binding and activation of the formyl peptide receptor (FPR) by
viral and formyl peptides. WEDWVGWI, a peptide with antiviral activity derived from the membrane proximal region of feline immunodeficiency
virus, binds with high affinity to FPR. The three tryptophans in the peptide are all essential for FPR binding, just as they were essential for antiviral
activity [S. Giannecchini, A. Di Fenza, A.M. D'Ursi, D. Matteucci, P. Rovero, M. Bendinelli, Antiviral activity and conformational features of an
octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein, J. Virol. 77 (2003)
3724]. Formyl-NleWEDWVGWI behaved as a weak partial agonist with FPR W190/N192 but a stronger partial agonist with FPR R190/K192 and
FPR R190/N192. Formyl-NleNleWEDWVGWI behaved as a full agonist toward all three FPRs but exhibited a much higher EC50 with W190/N192
FPR (300±45 nM) than for R190/K192 FPR (40±3 nM) or R190/N192 (60±8 nM). Formyl-MYKWPWYVWL preferentially activated R190/K192
and R190/N192 FPRs byN5 fold compared to W190/N192 FPR. Formyl-MFEDAVAWF, a peptide derived from a protein in Mycobacterium avium
subsp. paratuberculosis and formyl-MFTFEPFPTN, a peptide derived from the N-terminus of chemotaxis inhibitory protein of Staphylococcus aureus
with an added N-terminal formyl-methionine exhibited the greatest selectivity for R190/K192 and R190/N192 FPRs with ∼10 fold lower EC50s than
that observed with FPRW190/N192. Thus, individuals with the W190 polymorphism may display a reduced ability to detect certain formyl peptides.
© 2007 Elsevier B.V. All rights reserved.Keywords: Formyl peptides; Signal Transduction; G protein-coupled receptor; polymorphism; Feline immunodeficiency virus; Chemotaxis inhibitory protein of
Staphylococcus aureus1. Introduction
Neutrophils play an essential role in innate immunity. In ad-
dition to activating phagocytosis and secreting superoxides andAbbreviations: FPR, formyl peptide receptor; CHIPS, chemotaxis inhibitory
protein of Staphylococcus aureus; CHO S, Chinese hamster ovary cells designed
for suspension culture; HRSV, human respiratory syncytial virus; FIV, feline
immunodeficiency virus; fMLF, N-formyl-methionyl-leucyl-phenylalanine;
FLIPr, FPRL1 inhibitory protein; AIDS, Acquired Immunodeficiency Syndrome;
SIV, Simian Immunodeficiency Virus; HIV, human immunodeficiency virus;
SARS, severe acute respiratory syndrome;GP-41, 41 kilodalton glycoprotein; GP-
36, 36 kilodalton glycoprotein; HR, Heptade Repeat; FITC, Fluorescein
isothiocyanate; formyl-Nle-Leu-Phe-Nle-Tyr-Lys-FITC, formyl-Nle-Leu-Phe-
Nle-Tyr-Lys labeled at the Lys residue with Fluorescein isothiocyanate; formyl-
Nle-Leu-Phe-Nle-Tyr-Lys, labeled at the Lys residuewithAlexa FluorN-hydroxy-
succinimide; fMLF, formyl-Met-Leu-Phe; TMH, transmembrane helix; FPRL1,
formyl peptide receptor like 1; GTPγS, guanosine 5′-3-O-(thio)triphosphate
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doi:10.1016/j.bbadis.2007.06.001hydrolytic enzymes, the neutrophil must be able to chemotax, or
migrate toward the source of a chemoattractant [1,2]. The formyl
peptide receptor (FPR) is a chemoattractant G protein-coupled
receptor found on the surface of phagocytes and it is thought to
play an important role in allowing phagocytic cells to recognize
the presence of bacteria [3] and damaged cells, since only eu-
bacteria, mitochondria, and chloroplasts initiate their protein
synthesis with formyl-methionine [4]. FPR expressing cells also
exhibit chemotaxis toward peptides derived from the GP-41
envelope protein of HIV-1 [5,6]. A peptide derived from herpes
simplex virus type 2 elicited chemotaxis and superoxide pro-
duction in neutrophils in a process that appeared to involve FPR
[7]. In addition, we recently observed that peptides from the
proximal membrane region of the fusion proteins of human
immunodeficiency viruses 1 and 2, severe acute respiratory syn-
drome coronavirus, coronaviruses 229E and HKU, and Ebola
virus were potent inhibitors of FPR [8]. Thus FPR appears to
respond to the presence of virally derived peptides in addition to
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see [9]). Two proteins secreted by Staphylococcus aureus are
inhibitors of FPR ([10–12]). Chemotaxis inhibitory factor of S.
aureus (CHIPS) inhibits FPR and the C5a receptor and a
homologue of CHIPS, FPRL1 inhibitory protein (FLIPr) inhi-
bits FPRL1 and to a lesser extent FPR, but not C5a. The N-
terminus of CHIPS is essential for binding to FPR since removal
of the n-terminal phenylalanine reduces affinity for FPR ∼1000
fold. Peptides derived from the N-terminus are also inhibitors of
FPR but with ∼10,000 fold lower affinity than CHIPS.
Polymorphisms in FPR are very common. Sahagun-Ruiz et
al. [13] did an extensive haplotype investigation of FPR and
reported finding at least 23 haplotypes for FPR. No polymorph-
isms were found in the closely related receptor FPRL1 [13]. At
present there is no explanation for the wide sequence diversity of
FPR. Numerous studies have indicated that patients with
aggressive periodontitis exhibit a ∼2 fold reduction in chemo-
taxis toward fMLF [14–19] indicating that a reduced ability to
exhibit chemotaxis toward formyl peptides may be associated
with this disease. Several studies have attempted to correlate
FPR polymorphisms with aggressive periodontitis but have
produced conflicting results [20–22].
Lentiviruses are associated with immunological impairment
in their respective hosts, and both human immunodeficiency and
feline immunodeficiency viral infections increase the likelihood
of secondary bacterial infections [23,24]. Recently, Kubes et al.
[25] demonstrated that feline neutrophils exhibited a marked
(N90%) reduction of neutrophil chemotaxis toward fMLF
following infection with FIV. Ueda et al. noted that the HIV-1
envelope GP-41was able to downregulate the expression of FPR
and several chemokine receptors at low nanomolar concen-
trations, and that the downregulation of FPR and the chemokine
receptors was dependent upon expression of CD4 [26].
Peptides derived from the HR2 and proximal membrane
regions of HIV-1, SIV, HRSV, human parainfluenza virus type
3, measles virus, and a coronavirus have all been shown to be
able to block virus infection [27–30]. An eight mer peptide
derived from the proximal membrane region of FIV GP-36,
WEDWVGWI, was a potent (low nanomolar) inhibitor of FIV
infection [31]. The three W residues were all essential for
activity whereas the other residues were unimportant for activity.
We previously observed that FPR W190/N192 exhibited an
enhanced affinity to bind some viral peptides but had a reduced
affinity for the formyl peptide formyl-NleLeuPhe when
compared with FPR R190/N192 or FPR R190/K192 [8]. Here
we assessed whether the three W residues in WEDWVGWI
essential to viral inhibition [31] are also are important in FPR
binding. We also undertook a more extensive analysis of three
FPR polymorphisms using a variety of formyl peptides of
varying sequences in order to identify formyl peptides which
might behave markedly different toward the different polymor-
phisms. We identified several formyl peptides that exhibit high
selectivity for activation of R190/K192 and R190/N192 com-
pared with W190/N192. We also identified possible secondary
structure changes which might result from amino acid changes
by secondary structure prediction [32] and correlateld these
structural changes with altered binding and activation of FPR.2. Materials and methods
2.1. FPR expressing cells
CHO S cells expressing W190/N192, R190/K192, and R190/N192 were
prepared as described previously [8].
2.2. Materials
Peptides were obtained from Genscript and were N75% pure. Mass spectral
data was provided with each peptide and the major mass peak matched the
expected mass of the peptide in all cases. WEDWVGWI, AEDWVGVWI,
WEDAVGWI, and WEDWVGAI were N acetylated and amidated at the C-
terminus. All formyl peptides and had free C-termini. FTFEPFPTN had a free N-
terminus and a free C-terminus. Formyl-Nle-Leu-Phe was obtained from Sigma
and used without further purification. CHIPS was purchased from Cell Sciences.
2.3. FACScan analysis of ligand binding to FPR W190/N192,
R190/K192 or R190/N192 expressed in CHO-s cells
CHO S cells (100 μl in Gibco CHO-S-SFMII) were added to 3 mM KCl,
100 mM NaCl, 10 mM sodium phosphate, pH 7.4, 1 mM Mg++, 1 mM Ca++
containing 5% fetal bovine serum and incubated at 4 °C for 60 min with varying
concentrations peptide and 0.38 nM formyl-Nle-Leu-Phe-Nle-Tyr-Lys-FITC.
The mean fluorescence of the cells was determined, and the mean fluorescence
observed in non-expressing CHO S cells (non-specific binding) was subtracted.
The Ki was then determined by nonlinear least squares analysis using the known
Kd for formyl-Nle-Leu-Phe-Nle-Tyr-Lys-FITC for each FPR variant [8] and the
observed EC50 of each peptide. The Ki was determined from the equation
Ki =EC50/(1+(ligand/Kd) using the graphics/statistics program Graphpad Prizm.
2.4. Downregulation of surface FPR
CHO S cells expressing FPR were incubated in Gibco CHO-S-SFMII at
37 °C for 1 h (or the indicated time for Fig. 2A) with the indicted concentration of
peptide. DMSO was 0.4% in all cases. The cells were washed 2× with 10 ml
10 mM phosphate, pH 7.4, 3 mM KCl, 100 mM NaCl at 4 °C. The cells were
resuspended in 100 mM NaCl, 3 mM KCl, 10 mM sodium phosphate, pH 7.4,
1 mM Mg++, 1 mM Ca++, 5% fetal bovine serum and 50 nM formyl-Nle-Leu-
Phe-Nle-Tyr-Lys-FITC and incubated for 1 h at 4 °C and analyzed by FAScan as
describe above. For the receptor recovery experiment, the cells were washed 2×
with 10 ml 10 mM phosphate, pH 7.4, 3 mM KCl, 100 mM NaCl at 4 °C after
incubation with peptide, resuspended in Gibco CHO-S-SFMII at 37 °C for the
indicated time. Then the cells were washedwith 10ml 10mMphosphate, pH 7.4,
3 mMKCl, 100 mMNaCl at 4 °C and then analyzed by FACScan as above. The
mean fluorescence of the cells was determined, and the mean fluorescence
observed in non-expressing CHO S cells (non-specific binding) was subtracted.
The data were then analyzed by nonlinear least squares analysis and the EC50 and
Dmax determined. For partial agonist activity,Dmax was the % downregulation of
FPRs W190/N192, R190/K192, or R190/N192 compared with 20 μM formyl-
Nle-Leu-Phe carried out on the same day.
2.5. Statistical analysis
Experimental results are expressed as the mean±standard error of the mean.
The significance was evaluated by unpaired t test (2 tailed) using the computer
program Graphpad Prizm 2.0.
3. Results and discussion
FIV peptides (N-acetylated andC-amidated) derived from the
proximal membrane region of GP-36 have been assessed for
antiviral activity [31]. Therefore N-acetylated and C-amidated,
WEDWVGWI, AEDWVGVWI, WEDAVGWI, and WEDWV-
GAI were synthesized and evaluated for their ability to inhibit
Fig. 1. Inhibition of formyl-Nle-Leu-Phe-Nle-Tyr-Lys-FITC binding by 5 μM
WEDWVGWI, AEDWVGVWI, WEDAVGWI, and WEDWVGWI in FPRs
R190/N192, R190/K192, or W190/N192.
Fig. 2. (A) Downregulation of FPR surface expression in response to
preincubation at 37 °C for the indicated times with 3 μM formyl-Nle-Leu-Phe
for FPR R190/N192 (▪), R190/K192 (○) or W190/N192 (♦). (B) Recovery
from downregulation with 3 μM formyl-Nle-Leu-Phe for 60 min at 37 °C after
its removal for FPR R190/N192 (▪), R190/K192 (○) or W190/N192.
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shows the effect of these peptides on binding to W190/N192,
R190/K192, and R190/N192. Only WEDWVGWI exhibited
appreciable inhibition similar to what Giannecchini et al. [31]
observed for inhibition of viral infection by FIV inhibition. The
dose dependence of WEDWVGWI, formyl-NleWEDWVGWI,
and formyl-NleNleWEDWVGWI inhibition of formyl-Nle-
Leu-Phe-Nle-Tyr-Lys-FITC binding to W190/N192, R190/
K192, and R190/N192 was determined. The results are shown
in Table 1. Thus the addition of a formyl-Nle had no affect on
affinity and the addition of formyl-NleNle increased the affinity
to FPR∼2-fold. W190/N192 exhibited a∼2 fold lower affinity
for all three peptides.
Since downregulation is a hallmark of receptor activation
[33] and the trafficking of FPR expressed in CHO cells to
endocytotic vesicles following treatment with fMLF has been
thoroughly investigated [34], we chose this assay as a highly
precise way to evaluate ligand activation of receptor. Fig. 2A
shows a time course of loss of surface receptor for the three FPR
variants following treatment with 3 μM formyl-Nle-Leu-Phe.
All exhibited t1/2 of ∼5–6 min but W190/N192 downregulated
to a lesser maximum extent. Fig. 2B shows recovery of surface
receptor after treatment with formyl-Nle-Leu-Phe for 1 h. AllTable 1








* Pb0.001 W190/N192 vs. either R190/N192 or R190/K192.
** Pb0.0001 W190/N192 vs. either R190/N192 or R190/K192.
*** Pb0.0001 vs. both other variants.three variants exhibited partial recovery of surface receptor after
downregulation with slightly higher recovery observed with
W190/N192. We then determined the peptides concentration
dependent downregulation surface expression of the receptor to
assess whether the peptides exhibited agonist, partial agonist, or
antagonist activity. As we observed for other viral peptides [8],
WEDWVGWI did not cause any downregulation at concentra-
tions up to 25 μM, but 25 μM WEDWVGWI inhibited the
downregulation with 300 nM formyl-Nle-Leu-Phe by ∼50% in
all three FPRs (data not shown). However, formyl-Nle-







9.5±0.2 ⁎⁎⁎ 71±4 ⁎⁎⁎
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partial agonist activity was observed with W190/N192 (34±
3%, Pb0.0001 vs. either R190/K192 or R190/N192), and
greater partial agonist activity was observed with R190/K192
(55±2%) and R190/N192 (58±4%). W190/N192 also exhib-
ited a higher EC50 for downregulation than R190/K192 or
R190/N192 but the difference was not significant. Formyl-
NleNleWEDWVGWI behaved as a full agonist for all three
FPRs (Fig. 4A), but the EC50 for W190/N192 (300±40 nM,
Pb0.0001 vs. either R190/K192 or R190/N192) was 5–7 fold
higher than either R190/K192 (40±3 nM) or R190/N192 (60±
8 nM) despite the observation that the Kis differed by only two
fold. The observed EC50s were more than 10 fold below the
respective Kis for R190/K192 and R190/N192 and 3 fold
below the Ki of W190/R190, implying that formyl-NleNle-
WEDWVGWI was 3 times more effective in activating R190/
K192 and R190/N192 thanW190/N192. This large difference in
EC50 vs. Ki is in marked contrast to what we observe with
formyl-Nle-Leu-Phe (Fig. 3A) where the EC50s are similar to the
Ki s we previously reported [8]; EC50=175±20 vs. Ki =160±25Fig. 3. Downregulation of FPR surface expression in response to preincubation
with varying concentrations of formyl-Nle-Leu-Phe (A) or formyl-Nle-
WEDWVGWI (B) with FPR R190/N192 (▪), R190/K192 (○) or W190/N192
(♦). Maximum downregulation with formyl-Nle-Leu-Phe was 83±2%, 74±1%,
and 60±2% for R190/N192, R190/K192, and W190/N192, respectively.
Fig. 4. Downregulation of FPR surface expression in response to preincubation
with varying concentrations of formyl-NleNleWEDWVGWI (A) or formyl-
NleNleWEDAVGWI (B) with FPR R190/N192 (▪), R190/K192 (♦) or W190/
N192 (♦).for W190/N192; EC50=75±5 vs. Ki =62±8 for R190/K192;
EC50=50±7 vs. Ki =67±16 for R190/N192. Thus, formyl-
NleNleWEDWVGWI appears to behave as a “super agonist”
with R190/K192 and R190/N192, so that occupation of only 5%
of the receptors is able to bring about the internalization of 50%
of them. We also tested formyl-NleNleWEDAVGWI (Fig. 4B)
for its ability to cause downregulation of the receptor. Its
behavior was essentially identical to that seen with formyl-
NleNleWEDWVGWI. This is in contrast to WEDAVGWI
whichwasN10 foldweaker thanWEDWVGWI in binding to the
three FPRs. We also tested formyl-NleNleWED. This peptide
exhibited very little downregulation at concentrations up to
50 μM with all three FPRs. Thus the VGWI portion of the
peptide, formyl-NleNleWEDWVGWI, appears to be essential
for FPR activation.
We tested formyl-MYVKWPWYVWL, which we had pre-
viously shown to have essentially identical Kis for W190/N192,
R190/K192 and R190/N190 [8] of 130 nM, for its ability to
downregulate surface receptor (Fig. 5A). R190/K192 exhibited
the lowest EC50 of 44±4 nM about 3 fold below the observed Ki
and a maximum downregulation very similar (89%) to that seen
with formyl-Nle-Leu-Phe (Fig. 3A). R190/N192 had a 2 fold
Fig. 5. Downregulation of FPR surface expression in response to preincubation
with varying concentrations of formyl-MYKWPWYVWL (A) or formyl-
MFEDAVAWF (B) or formyl-MMFTFEPFPTN (C) with FPR R190/N192 (▪),
R190/K192 (○) or W190/N192 (♦).
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regulation similar to that observed with formyl-Nle-Leu-Phe.
W190/N192 had a EC50 14 fold greater than K192/N192
(P=0.0002) and 6 fold greater than R190/N192 (P=0.0006) and
amaximum downregulation slightly reduced (74%) compared to
that seen with formyl-Nle-Leu-Phe. This reduction is consistent
with the reduced (65%) stimulation of GTPγS binding ofW190/
N192 FPR by 300 nM formyl-MYVKWPWYVWL compared
to R190/K192 or R190/N192 FPRs reported previously [8].
We carried out a protein blastp search (http://www.ncbi.
nlm.nih.gov/BLAST/Blast.cgi?PAGE=Proteins&PROGRAM=
blastp&BLAST_PROGRAMS=blastp&PAGE_TYPE=BlastSearch&SHOW_DEFAULTS=on) with the sequence
MMWEDAVGWI (Nle is a oxidation resistant analog of M)
to identify sequences which were most similar in sequence to
formyl-NleNleWEDAVGWI. Bacteria (taxid:2) was used as the
search organism. Two sequences of reasonable similarity to
MMWEDAVGWI at their N-terminus were identified (Only N-
termini would be formylated). One was protein MAP 4176 from
Mycobacterium avium subsp. paratuberculosis and the other
was protein JNB 01080 from Janibacter. Only the MAP 4176
sequence was investigated and it had MFEDAVAWF as its N-
terminal sequence. Formyl-MFEDAVAWF was synthesized and
evaluated for binding and downregulation. Formyl-MFEDA-
VAWF's Ki was 4 fold higher for W190/N192 than for R190/
K192 or R190/N192 (Table 1). We also determined the EC50 for
downregulation. Formyl-MFEDAVAWF behaved as a full ago-
nist with all three FPRs (Fig. 5B) and this peptide activates
W190/N190 ∼10 fold more weakly than either R190/K192 or
R190/N192. EC50s for W190/N192, R190/K192 and R190/
N192 were 13,000±1000 nM, 1000± 80 nM, and 1500±
100 nM, respectively (Pb0.0001, W190/N192 vs. either R190/
K192 or R190/N192).
Formyl-MFEDAVAWF exhibited some similarity to the
N-terminus of CHIPS so we synthesized the peptide
FTFEPFPTN, which corresponds to the N-terminus of CHIPS,
and also formyl-MFTFEPFPTN. We tested commercially
available CHIPS for its ability to inhibit formyl-Nle-Leu-Phe-
Nle-Tyr-Lys-FITC binding but could not detect any inhibition at
50 nMwith any of the FPR variants. FTFEPFPTN produced very
little inhibition of formyl-Nle-Leu-Phe-Nle-Tyr-Lys-FITC bind-
ing also with at most 30% inhibition at 100 μM with the three
FPR variants. Formyl-MFTFEPFPTN was very effective at
inhibiting all three variants (Table 1) and exhibited significantly
different Kis for W190/N192, R190/K192 and R190/N192 with
Kis of 71±4 nM, 16±0.7 nM, and 9.5± 0.2 nM, respectively
(Pb0.0001 for each variant vs. each of the other two). We also
tested formyl-MFTFEPFPTN for its ability to downregulate
W190/N192, R190/K192 and R190/N192 (Fig. 5C). The EC50s
were 19±1 nM, 3.1±0.2 nM, and 6.8±100 nM, respectively
(Pb0.0001 for each variant vs. each of the other two) and the
maximum downregulation was very similar to that see with
formyl-Nle-Leu-Phe. The addition of formyl-methionine to the
N-terminus of FTFEPFPTN enhanced the affinity ∼10,000 fold,
and formyl-MFTFEPFPTN exhibited an affinity similar to that
seen with CHIPS (Kd∼35 nM) [11]. It should be noted that while
CHIPS was originally isolated as a secreted protein from S.
aureus [35], many of the experiments were done using CHIPS
expressed in Escherichia coli [10,11,36], and the properties of
FLIPr were determined only on the E. coli expressed protein
[12]. E. coli expressed proteins would be expected to have an N
terminal formyl-methionine. However, the authors noted no
difference with the E. coli expressed CHIPS [11].
3.1. Effects of variants W190 and K192 on predicted secondary
structure
We analyzed the possible effects on secondary structure that
might occur in response to changes at positions 190 or 192 using
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secondary structure (http://bioinf.cs.ucl.ac.uk/psipred/) [32].
The results are shown in Table 2. The sequence prediction of
rhodopsin is also given since its crystal structure is known [37].
TMH V in rhodopsin begins at E202 and is the first residue
predicted to have a non-zero value for helix propensity.
Underlined residues in the rhodopsin sequence are identical in
FPR. W190/N192 exhibits a reduced helix propensity of 113 vs.
140 for R190/N192 or 137 for R190/K192 (summation of helix
propensity for residues N-terminal to FPR P213 or rhodopsin
P215; underlined in Table 2). PRISPED analysis of all three FPR
sequences suggests that TMH V is longer than that observed
with rhodopsin as we previously suggested [8] based on Kyte
and Doolittle [38] analysis, but the predicted beginning of helix
V varies depending upon the FPR sequence. Most interesting is
the predicted effect W190/N192 has on the helix propensity of
the residues N-terminal to FPR P213. P213 was previously
shown to be important in FPR structure, since P213A did not
fold properly and was retained in the endoplasmic reticulum
[39]. Since proline is secondary amine, it cannot hydrogen bond
and this destabilizes the helix N-terminal to the proline. In
rhodopsin, the carbonyl of H211 hydrogen bonds to the carboxy-
late of E122 (which can only occur if H211 is not hydrogen
bonded to P215, a residue highly conserved in GPCR [40]). The
H211 carbonyl is important in rhodopsin activation, since its
hydrogen bonding with E122 is disrupted upon rhodopsin
activation [41]. We have previously shown that F110, which is
analogous to E122 of rhodopsin, is important in FPR activation,
since the F110A mutant exhibits very poor coupling to G
protein, and very poor chemotaxis toward fMLF [42]. While
FPR F110 cannot hydrogen bond to the carbonyl of FPR G209
(analogous to rhodopsin H211), aromatic rings do exhibit
energetically favorably interactions with carbonyl oxygens [43].
F110 interaction with the G209 carbonyl and disruption of the
F110–G209 interaction by ligand binding could be important inTable 2
Structure prediction by PSIPRED
Conf, confidence; Pred, predicted secondary structure; AA, amino acid; C, coil; H, h
confidence prediction. Underlined bold, identical between rhodopsin and FPR; und
indicated in italics [40].FPR activation. The fact that W190/N190 is predicted to exhibit
lower helicity near G209 may alter its ability to be activated in
response to ligand binding (Table 2).
We had previously observed that the polymorphism W190/
N192 exhibited slightly reduced (∼2 fold) affinity for formyl-
Nle-Leu-Phe but a 4 fold higher affinity for several virally
derived peptides when compared with either R190/K192 or
R190/N192 [8]. Here we observed that the three W in the
peptide WEDWVGWI are all essential for FPR binding, just
as they are essential for antiviral activity [31]. This could be
due to changes in structure of the peptide since WEDWVGAI
was shown by NMR in DMSO–water solution to adopt a
different structure than WEDWVGWI [31]. Nonetheless, the
correlation between antiviral activity and ability to interact
with FPR is an intriguing one, especially since FPR is able to
interact with the proximal membrane region of many viruses
[8].
We also evaluated several formyl-Nle derivatives of
WEDWVGWI and formyl-MYVKWPWYVWL in order to
identify possible formyl peptide ligands which exhibit markedly
different activities toward the W190/N192 polymorphism. We
also identified a similar peptide from blastp bacterial sequence
data bases. Most of the peptides evaluated interacted similarly
with R190/K192 and R190/N192 FPRs, but both formyl-
MYVKWPWYVWL and formyl- MFTFEPFPTN activated
R190/K192 ∼2fold more effectively than R190/N192. W190/
N192was activatedmuchmore poorly than either R190/K192 or
R190/N192 by all the formyl peptides investigated here and
exhibited much greater differences in EC50s than observed for
formyl-Nle-Leu-Phe. This was true even though W190/N192
bound formyl-NleNleWEDWVGWI and formyl-MYVKWP-
WYVWLwith similar affinity to that observed with R190/K192
or R190/N192. This implies that a W at position 190 interferes
with the activation process but does not alter the binding
constant appreciably with these peptides.elix; E, extended. Numbers in parentheses are the summation of the underlined
erlined, similar between rhodopsin and FPR. The highly conserved proline is
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M. avium subsp. paratuberculosis, formyl-MFEDAVAWI,
which activates R190/K192 and R190/N192 ∼10 fold better
than W190/R190. This could be important since M. avium
subsp. paratuberculosis is a facultative intracellular pathogen
of macrophages which is associated with Johne's disease in
cattle and may be associated with Crohn's disease in humans
[44,45].
Thus, the replacement of R190 by W190 produces profound
effects on the activation of the receptor by six different formyl
peptides composed of nine or more residues but a much lesser
effect on the tri-peptide formyl-Nle-Leu-Phe. For formyl-
MYVKWPWYVWL, formyl-NleNleWEDWVGWI, formyl-
NleNleWEDAVGWI, and formyl-NleWEDWVGWI, the
major difference betweenW190/N192 and R190/N192 or R190/
K192 is the ability to activate the receptor and the difference in
Ki is small (~2 fold or less). For formyl-MFTFEPFPTN and
formyl-MFEDAVAWF both Ki and EC50 were markedly
increased in W190/N192 compared to either R190/N192 or
R190/K192. It should be remembered that Ki does not reflect the
binding energy used to promote conformational change in the
receptor, since the latter is potential energy. The EC50 for
downregulation, therefore, may be a better representation of the
total binding energy.
The fact that the addition of formyl-Nle to WEDWVGWI
had little effect (b20%) on its affinity but the addition of
formyl-Met to FTFEPFPTN enhanced the affinity ∼10,000
fold implies a marked difference in the mode of binding of
the two peptides. One possibility is that WEDWVGWI occu-
pies the formyl-Met (or formyl-Nle) binding pocket but
FTFEPFPTN does not. The fact that formyl-MFTFEPFPTN
binds with similar affinity to CHIPS may indicate that in the
intact protein, some residue of the protein is able to interact
with the formyl-Met binding site and substitute for it but not
activate the receptor.
We had previously proposed that R205 in TMH V interacts
with the C-terminus of fMLF [46] and is essential for binding
this tri-peptide, but is much less essential in binding larger
peptides like formyl-Nle-Leu-Phe-Nle-Tyr-Lys-FITC [39]. We
have also shown that W190 quenches the fluorescence of
formyl-Nle-Leu-Phe-Nle-Tyr-Lys-AlexaFluor, indicating
W190 must reside close to the AlexaFluor moiety when this
peptide is bound to FPR [8]. These findings are both con-
sistent with the larger effects observed with W190/N192 with
longer peptides since only peptides much longer than three
residues are likely to interact near R or W190. In addition,
provided that formyl-MFTFEPFPTN is a good model for
CHIPS binding, this might indicate that the polymorphism
W190/N192 would be more resistant to inhibition by CHIPS
and thus those with this polymorphism might control in-
fections with S. aureus better than those with the R190 poly-
morphism. Recent studies have indicated that a high
percentage of normal individuals (24/24) express antibodies
to CHIPS [47], so that a polymorphism that was more re-
sistant to its effect might exhibit a selective advantage, since
W190/N192 retains most of its ability to interact with for-
mylated tri peptides.Acknowledgments
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